Transaction in Own Shares

PureTech Health PLC
14 November 2023
 

14 November 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:             

13 November 2023



Number of ordinary shares purchased:

44,425



Highest price paid per share:

171.60p



Lowest price paid per share:

164.00p



Volume weighted average price paid per share:

170.44p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,283,743 ordinary shares in treasury and has 273,184,416 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 273,184,416 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

13/11/2023

08:04:02

496

164

XLON

00378038941TRLO0.1.1

13/11/2023

09:48:24

10

164

XLON

00378052016TRLO0.1.1

13/11/2023

10:17:04

223

165

XLON

00378054686TRLO0.1.1

13/11/2023

11:16:02

496

167.6

CHIX

00378060065TRLO0.1.1

13/11/2023

11:16:02

1488

167.6

XLON

00378060066TRLO0.1.1

13/11/2023

11:16:02

496

167.6

CHIX

00378060064TRLO0.1.1

13/11/2023

11:16:05

215

166.4

AQXE

00378060067TRLO0.1.1

13/11/2023

11:41:48

440

168.2

XLON

00378062314TRLO0.1.1

13/11/2023

11:41:48

64

168.2

XLON

00378062315TRLO0.1.1

13/11/2023

12:35:05

878

167

XLON

00378067707TRLO0.1.1

13/11/2023

12:35:05

496

167

CHIX

00378067708TRLO0.1.1

13/11/2023

12:35:05

610

167

XLON

00378067710TRLO0.1.1

13/11/2023

12:35:05

496

167

CHIX

00378067709TRLO0.1.1

13/11/2023

13:17:44

492

169

XLON

00378071889TRLO0.1.1

13/11/2023

13:20:04

793

169

XLON

00378072057TRLO0.1.1

13/11/2023

13:57:23

992

168.6

XLON

00378076134TRLO0.1.1

13/11/2023

14:26:09

826

169.6

XLON

00378080013TRLO0.1.1

13/11/2023

14:36:58

3099

171.4

XLON

00378087035TRLO0.1.1

13/11/2023

14:36:58

3099

171.4

XLON

00378087036TRLO0.1.1

13/11/2023

14:36:58

3099

171.4

XLON

00378087037TRLO0.1.1

13/11/2023

14:36:58

3099

171.4

XLON

00378087038TRLO0.1.1

13/11/2023

14:37:12

1245

171.6

CHIX

00378087211TRLO0.1.1

13/11/2023

14:37:12

739

171.6

CHIX

00378087212TRLO0.1.1

13/11/2023

14:43:28

3099

171.4

XLON

00378090823TRLO0.1.1

13/11/2023

14:43:28

505

171.4

XLON

00378090824TRLO0.1.1

13/11/2023

14:54:32

10

168.6

AQXE

00378098041TRLO0.1.1

13/11/2023

14:54:33

10

168.6

AQXE

00378098044TRLO0.1.1

13/11/2023

14:54:33

1055

168.6

AQXE

00378098045TRLO0.1.1

13/11/2023

15:41:21

15

170.2

CHIX

00378123644TRLO0.1.1

13/11/2023

15:42:06

11

170.2

CHIX

00378124059TRLO0.1.1

13/11/2023

15:42:43

23

170.2

CHIX

00378124337TRLO0.1.1

13/11/2023

16:05:15

2017

171.4

XLON

00378134889TRLO0.1.1

13/11/2023

16:05:15

1002

171.4

XLON

00378134890TRLO0.1.1

13/11/2023

16:05:15

2017

171.4

XLON

00378134891TRLO0.1.1

13/11/2023

16:05:15

214

171.4

XLON

00378134892TRLO0.1.1

13/11/2023

16:05:15

22

171.4

XLON

00378134893TRLO0.1.1

13/11/2023

16:05:15

1176

171.4

XLON

00378134894TRLO0.1.1

13/11/2023

16:05:28

447

171.6

CHIX

00378134979TRLO0.1.1

13/11/2023

16:17:07

68

171.4

XLON

00378140061TRLO0.1.1

13/11/2023

16:17:07

23

171.4

XLON

00378140062TRLO0.1.1

13/11/2023

16:17:35

61

171.4

XLON

00378140511TRLO0.1.1

13/11/2023

16:18:52

282

170.6

XLON

00378141035TRLO0.1.1

13/11/2023

16:24:30

244

171.4

CHIX

00378144620TRLO0.1.1

13/11/2023

16:24:30

464

170.6

BATE

00378144621TRLO0.1.1

13/11/2023

16:24:30

496

170.6

BATE

00378144622TRLO0.1.1

13/11/2023

16:24:30

452

170.6

BATE

00378144623TRLO0.1.1

13/11/2023

16:24:52

44

170.6

BATE

00378144900TRLO0.1.1

13/11/2023

16:24:52

343

170.6

BATE

00378144901TRLO0.1.1

13/11/2023

16:24:52

176

170.4

XLON

00378144902TRLO0.1.1

13/11/2023

16:24:53

81

170.4

XLON

00378144934TRLO0.1.1

13/11/2023

16:26:06

705

170.4

XLON

00378145687TRLO0.1.1

13/11/2023

16:26:06

84

170.4

XLON

00378145689TRLO0.1.1

13/11/2023

16:26:41

244

171.2

CHIX

00378145918TRLO0.1.1

13/11/2023

16:27:22

265

170.4

XLON

00378146167TRLO0.1.1

13/11/2023

16:28:44

256

171.4

TRQX

00378146961TRLO0.1.1

13/11/2023

16:29:40

99

171

CHIX

00378147704TRLO0.1.1

13/11/2023

16:29:40

938

171

CHIX

00378147705TRLO0.1.1

13/11/2023

16:29:41

192

171.4

TRQX

00378147712TRLO0.1.1

13/11/2023

16:29:46

1

171.2

CHIX

00378147809TRLO0.1.1

13/11/2023

16:29:47

96

171.4

TRQX

00378147812TRLO0.1.1

13/11/2023

16:29:47

2119

171

XLON

00378147814TRLO0.1.1

13/11/2023

16:29:47

458

171.2

CHIX

00378147813TRLO0.1.1

13/11/2023

16:29:57

96

171.4

TRQX

00378147973TRLO0.1.1

13/11/2023

16:29:58

624

171

XLON

00378147979TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings